open access

Vol 15, No 6 (2019)
Congress abstract / Abstract
Published online: 2020-01-10
Get Citation

EOTTD Meeting in Berlin, July 5–6, 2019

Magdalena Miedzińska
DOI: 10.5603/OCP.2019.0037
·
Oncol Clin Pract 2019;15(6):339-341.

open access

Vol 15, No 6 (2019)
CONGRESS REPORT
Published online: 2020-01-10

Abstract

On the begining of July 2019 took place international EOTTD conference (The European Organization for the Treatment of Trophoblastic Disease). The meeting place was in the one of the largest university hospitasl in Europe, the Charité hospital in Berlin. The main postulate of this year's EOTTD conference was to emphasize the role of instant and correct clinical, biochemical, pathomorphological, immunohistochemical and genetic diagnosis, conducting intensive, compliant with treatment recommendations and the need to assess the quality of life of patients. National registers, the creation of reference centers and their cooperation should serve to achieve these goals.

Abstract

On the begining of July 2019 took place international EOTTD conference (The European Organization for the Treatment of Trophoblastic Disease). The meeting place was in the one of the largest university hospitasl in Europe, the Charité hospital in Berlin. The main postulate of this year's EOTTD conference was to emphasize the role of instant and correct clinical, biochemical, pathomorphological, immunohistochemical and genetic diagnosis, conducting intensive, compliant with treatment recommendations and the need to assess the quality of life of patients. National registers, the creation of reference centers and their cooperation should serve to achieve these goals.

Get Citation

Keywords

gestational trophoblastic disease; gestational throphoblastic neoplasm

About this article
Title

EOTTD Meeting in Berlin, July 5–6, 2019

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 6 (2019)

Article type

Congress abstract / Abstract

Pages

339-341

Published online

2020-01-10

DOI

10.5603/OCP.2019.0037

Bibliographic record

Oncol Clin Pract 2019;15(6):339-341.

Keywords

gestational trophoblastic disease
gestational throphoblastic neoplasm

Authors

Magdalena Miedzińska

References (7)
  1. Bolze PA, Attia J, Massardier J, et al. EOTTD group. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer. 2015; 51(13): 1725–1731.
  2. FIGO Oncology Committee report: FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynecol Obstet. 2002; 77(3): 285–287.
  3. Frijstein MM, Lok CAR, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer. 2019; 109: 162–171.
  4. Bolze PA, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. 2017; 27(3): 554–561.
  5. Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017; 390(10110): 2343–2345.
  6. Frijstein MM, Lok CAR, van Trommel NE, et al. Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database. Gynecol Oncol. 2019; 152(2): 361–367.
  7. Gadducci A, Carinelli S, Guerrieri ME, et al. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol. 2019; 153(3): 684–693.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl